Currency In USD
| Previous Close | 6.85 |
| Open | 6.98 |
| Day High | 7.01 |
| Day Low | 6.9 |
| 52-Week High | 33.68 |
| 52-Week Low | 5.85 |
| Volume | 434,241 |
| Average Volume | 607,950 |
| Market Cap | 379.31M |
| PE | -2.4 |
| EPS | -2.91 |
| Moving Average 50 Days | 6.85 |
| Moving Average 200 Days | 14.76 |
| Change | 0.12 |
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Mar 01, 2026 2:45 PM GMT
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including r
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stag
Upstream Bio to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherlan